vs

Side-by-side financial comparison of Amarin Corp plc (AMRN) and CBAK Energy Technology, Inc. (CBAT). Click either name above to swap in a different company.

CBAK Energy Technology, Inc. is the larger business by last-quarter revenue ($58.8M vs $45.1M, roughly 1.3× Amarin Corp plc). CBAK Energy Technology, Inc. runs the higher net margin — -12.5% vs -23.3%, a 10.7% gap on every dollar of revenue. On growth, CBAK Energy Technology, Inc. posted the faster year-over-year revenue change (131.8% vs 7.0%). Over the past eight quarters, CBAK Energy Technology, Inc.'s revenue compounded faster (-0.0% CAGR vs -18.3%).

Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

CBAK Energy Technology, Inc. is a global supplier of lithium-ion battery products including high-performance cells, modules and battery packs. It serves key segments such as electric vehicles, stationary energy storage systems and consumer electronics, with core operations in China and a worldwide customer base.

AMRN vs CBAT — Head-to-Head

Bigger by revenue
CBAT
CBAT
1.3× larger
CBAT
$58.8M
$45.1M
AMRN
Growing faster (revenue YoY)
CBAT
CBAT
+124.8% gap
CBAT
131.8%
7.0%
AMRN
Higher net margin
CBAT
CBAT
10.7% more per $
CBAT
-12.5%
-23.3%
AMRN
Faster 2-yr revenue CAGR
CBAT
CBAT
Annualised
CBAT
-0.0%
-18.3%
AMRN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRN
AMRN
CBAT
CBAT
Revenue
$45.1M
$58.8M
Net Profit
$-10.5M
$-7.4M
Gross Margin
7.3%
Operating Margin
35.5%
-13.6%
Net Margin
-23.3%
-12.5%
Revenue YoY
7.0%
131.8%
Net Profit YoY
33.0%
-63.6%
EPS (diluted)
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRN
AMRN
CBAT
CBAT
Q1 26
$45.1M
Q4 25
$49.2M
$58.8M
Q3 25
$49.7M
$60.9M
Q2 25
$72.7M
$40.5M
Q1 25
$42.0M
$34.9M
Q4 24
$62.3M
$25.4M
Q3 24
$42.3M
$44.6M
Q2 24
$67.5M
$47.8M
Net Profit
AMRN
AMRN
CBAT
CBAT
Q1 26
$-10.5M
Q4 25
$-1.2M
$-7.4M
Q3 25
$-7.7M
$2.7M
Q2 25
$-14.1M
$-3.1M
Q1 25
$-15.7M
$-1.6M
Q4 24
$-48.6M
$-4.5M
Q3 24
$-25.1M
$17.6K
Q2 24
$1.5M
$6.4M
Gross Margin
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
47.1%
7.3%
Q3 25
44.7%
8.0%
Q2 25
69.2%
11.0%
Q1 25
59.8%
13.7%
Q4 24
-15.4%
13.1%
Q3 24
38.5%
15.6%
Q2 24
63.4%
26.6%
Operating Margin
AMRN
AMRN
CBAT
CBAT
Q1 26
35.5%
Q4 25
-12.9%
-13.6%
Q3 25
-22.4%
-6.6%
Q2 25
-22.0%
-8.7%
Q1 25
-39.9%
-8.2%
Q4 24
-84.3%
-26.0%
Q3 24
-59.5%
-1.9%
Q2 24
-0.8%
12.4%
Net Margin
AMRN
AMRN
CBAT
CBAT
Q1 26
-23.3%
Q4 25
-2.5%
-12.5%
Q3 25
-15.6%
4.4%
Q2 25
-19.4%
-7.6%
Q1 25
-37.4%
-4.5%
Q4 24
-78.0%
-17.8%
Q3 24
-59.4%
0.0%
Q2 24
2.3%
13.5%
EPS (diluted)
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
$0.00
$-0.08
Q3 25
$-0.02
$0.03
Q2 25
$-0.03
$-0.03
Q1 25
$-0.04
$-0.02
Q4 24
$-0.12
$-0.05
Q3 24
$-0.06
$0.00
Q2 24
$0.00
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRN
AMRN
CBAT
CBAT
Cash + ST InvestmentsLiquidity on hand
$307.8M
$8.3M
Total DebtLower is stronger
$4.1M
Stockholders' EquityBook value
$112.7M
Total Assets
$645.8M
$426.2M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRN
AMRN
CBAT
CBAT
Q1 26
$307.8M
Q4 25
$302.6M
$8.3M
Q3 25
$286.6M
$10.5M
Q2 25
$298.7M
$45.7M
Q1 25
$281.8M
$9.6M
Q4 24
$294.2M
$11.0M
Q3 24
$305.7M
$24.2M
Q2 24
$306.7M
$44.1M
Total Debt
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
$4.1M
Q3 25
$4.8M
Q2 25
$4.9M
Q1 25
$4.1M
Q4 24
Q3 24
Q2 24
Stockholders' Equity
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
$459.3M
$112.7M
Q3 25
$458.9M
$121.4M
Q2 25
$464.9M
$118.2M
Q1 25
$473.7M
$120.8M
Q4 24
$486.2M
$121.7M
Q3 24
$531.4M
$131.2M
Q2 24
$551.9M
$126.6M
Total Assets
AMRN
AMRN
CBAT
CBAT
Q1 26
$645.8M
Q4 25
$670.8M
$426.2M
Q3 25
$659.8M
$363.9M
Q2 25
$670.1M
$333.1M
Q1 25
$655.7M
$311.5M
Q4 24
$685.3M
$302.2M
Q3 24
$750.6M
$293.5M
Q2 24
$799.9M
$279.6M
Debt / Equity
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
0.04×
Q3 25
0.04×
Q2 25
0.04×
Q1 25
0.03×
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRN
AMRN
CBAT
CBAT
Operating Cash FlowLast quarter
$29.8M
Free Cash FlowOCF − Capex
$16.1M
FCF MarginFCF / Revenue
27.3%
Capex IntensityCapex / Revenue
23.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$3.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
$15.3M
$29.8M
Q3 25
$-12.7M
$14.6M
Q2 25
$16.6M
$13.8M
Q1 25
$-12.5M
$-9.6M
Q4 24
$-13.3M
$9.6M
Q3 24
$-2.4M
$19.7M
Q2 24
$-2.7M
$2.9M
Free Cash Flow
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
$16.1M
Q3 25
$6.0M
Q2 25
$4.1M
Q1 25
$-22.3M
Q4 24
$3.9M
Q3 24
$16.5M
Q2 24
$2.5M
FCF Margin
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
27.3%
Q3 25
9.9%
Q2 25
10.2%
Q1 25
-63.9%
Q4 24
15.5%
Q3 24
37.1%
Q2 24
5.2%
Capex Intensity
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
23.4%
Q3 25
14.1%
Q2 25
23.8%
Q1 25
36.3%
Q4 24
22.5%
Q3 24
7.0%
Q2 24
0.9%
Cash Conversion
AMRN
AMRN
CBAT
CBAT
Q1 26
Q4 25
Q3 25
5.51×
Q2 25
Q1 25
Q4 24
Q3 24
1115.72×
Q2 24
-1.81×
0.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRN
AMRN

U.S$35.6M79%
Europe$4.9M11%
Rest-of-World (ROW)$2.8M6%
Licensing & Royalties$1.8M4%

CBAT
CBAT

Manufacturing Lithium Batteries$28.0M48%
Residential Energy Supply And Uninterruptable Supplies$17.8M30%
Light Electric Vehicles$12.9M22%
Precursor$108.0K0%

Related Comparisons